title: A human B-cell lymphoma line with a de novo multidrug resistance phenotype.
abstract: A human diffuse large cell lymphoma line (WSU-DLCL) expressing multidrug resistance (MDR) was established from a patient with primary chemotherapy-resistant disease. This cell line has the same phenotypic features as malignant cells from the patient. The established cell line has features of a mature B-cell neoplasm with no evidence for commitment to other lineages. WSU-DLCL grows in suspension forming relatively large clumps of cells with a doubling time of 20 hours. By light microscopic examination, the cells are very large with primitive lymphoid features, have a large amount of cytoplasm containing numerous vacuoles and an irregular outline. Immunophenotypic characterization by monoclonal antibodies and flow cytometric analysis showed a monoclonal IgM kappa B-cell phenotype with high expression of the multidrug-resistant P-glycoprotein compared with either normal peripheral blood lymphocytes or cells of the REH cell line. The cells were negative for T-cell and myeloid/monocyte antigens as well as Epstein-Barr virus nuclear antigen (EBNA). In addition, the cell line expressed high levels of MDR RNA. DNA histogram generated by flow cytometry indicated a DNA index of 1.83. Cytogenetic analysis confirmed hypertriploidy and showed complex chromosomal abnormalities including 14q+. This cell line should be a valuable tool to study the role of the MDR gene in the primary resistance of lymphomas to chemotherapy and to facilitate therapeutic investigations.
authors.affiliation: Department of Internal Medicine, Wayne State University, Detroit, Michigan.
authors.forename: R M
authors.initials: RM
authors.lastname: Mohammad
authors.forename: A N
authors.initials: AN
authors.lastname: Mohamed
authors.forename: M
authors.initials: M
authors.lastname: KuKuruga
authors.forename: M R
authors.initials: MR
authors.lastname: Smith
authors.forename: A
authors.initials: A
authors.lastname: al-Katib
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002460:Cell Line; D002869:Chromosome Aberrations / Q000235:genetics; D025063:Chromosome Disorders; D002898:Chromosomes, Human, Pair 8; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D015870:Gene Expression; D015322:Gene Rearrangement, B-Lymphocyte / Q000235:genetics; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000473:pathology; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D007145:Immunoglobulin kappa-Chains / Q000032:analysis; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000235:genetics* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000473:pathology; D010641:Phenotype; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D007145:Immunoglobulin kappa-Chains